<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131037</url>
  </required_header>
  <id_info>
    <org_study_id>LuTK01</org_study_id>
    <nct_id>NCT03131037</nct_id>
  </id_info>
  <brief_title>Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer</brief_title>
  <official_title>Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Candel Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Candel Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study of Gene Mediated Cytotoxic Immunotherapy (GMCI) in patients with&#xD;
      non-small cell lung cancer (NSCLC). The primary clinical end-point of the study is to&#xD;
      evaluate the safety of GMCI when combined with standard surgery for NSCLC. The primary&#xD;
      scientific objective is to determine the immunologic changes induced by GMCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this open-label, dose escalation clinical trial is to investigate the safety&#xD;
      of GMCI prior to surgery in patients with NSCLC. GMCI involves the use of aglatimagene&#xD;
      besadenovec (AdV-tk) injected into the tumor followed by oral valacyclovir prodrug to kill&#xD;
      tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune&#xD;
      stimulatory environment induces the body's immune system to detect and destroy cancer cells.&#xD;
      GMCI has been well tolerated in previous trials in multiple tumor types with clinical,&#xD;
      pathologic and immune responses.&#xD;
&#xD;
      AdV-tk will be injected intratumorally on day 0 during a standard of care staging procedure.&#xD;
      The prodrug, valacyclovir, will be administered orally at a fixed dose for 14 days following&#xD;
      the AdV-tk injection. Then standard of care surgical resection will be performed about 3&#xD;
      weeks after the AdV-tk injection. Chemotherapy and/or radiation may begin 6-8 weeks after&#xD;
      resection surgery. Choice of chemotherapy depends on the treating oncologist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety based on standard laboratory and clinical adverse event monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic changes</measure>
    <time_frame>12 months</time_frame>
    <description>The effect of GMCI on the histology and immune profile of the resected tumor. Systemic and intratumoral cytokine responses will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The PFS curves will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>The OS curves will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdV-tk (aglatimagene besadenovec) + valacyclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdV-tk (aglatimagene besadenovec) + valacyclovir</intervention_name>
    <description>AdV-tk will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically documented non-small cell carcinoma (cytology or histology) that is&#xD;
             accessible via standard-of-care staging procedures: (1) EBUS or (2) surgical&#xD;
             approaches (eg mediastinoscopy, mediastinotomy or VATS).&#xD;
&#xD;
          -  Resectable with negative lymph nodes based on imaging with histologic confirmation at&#xD;
             time of the staging procedure prior to AdV-tk injection&#xD;
&#xD;
          -  The tumor must be 4cm or greater in diameter based on imaging&#xD;
&#xD;
          -  ECOG Performance status of 0 or 1.&#xD;
&#xD;
          -  Granulocyte count (ANC) ≥ 1,000/mm3&#xD;
&#xD;
          -  Peripheral lymphocyte count ≥ 500/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dl&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x upper limit of normal&#xD;
&#xD;
          -  SGOT (AST) ≤ 3x upper limit of normal&#xD;
&#xD;
          -  Serum creatinine &lt; 2mg/dl&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 30ml/min&#xD;
&#xD;
          -  Patients must give study specific informed consent prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiotherapy and/or treatment with chemotherapeutic, cytotoxic, or immunologic agents&#xD;
             within 4 weeks prior to infusion of the vector.&#xD;
&#xD;
          -  Known immunodeficiency such as HIV infection&#xD;
&#xD;
          -  Active liver disease, including known cirrhosis or active hepatitis&#xD;
&#xD;
          -  Use of systemic corticosteroids (&gt;10 mg prednisone per day or equivalent) or other&#xD;
             systemic immunosuppressive drugs&#xD;
&#xD;
          -  Patient is pregnant or breast-feeding. Female patients of childbearing age must have&#xD;
             negative serum or urine pregnancy test within 1 week of beginning therapy. Subjects&#xD;
             must use acceptable means of birth control until 30 days after the vector injection.&#xD;
&#xD;
          -  Presence of any other life-threatening illness, such as unstable angina, severe oxygen&#xD;
             dependence, significant chronic obstructive pulmonary disease (COPD), end-stage liver&#xD;
             or renal disease. COPD will be considered significant if disease limits activities of&#xD;
             daily living, results in the inability to walk up 1 flight of stair, or requires home&#xD;
             oxygen.&#xD;
&#xD;
          -  Presence of known untreated brain metastases.&#xD;
&#xD;
          -  Prior bone marrow transplants (including stem cells) except autologous stem cell&#xD;
             transplant without immunosuppression is NOT considered an exclusion.&#xD;
&#xD;
          -  Known sensitivity or allergic reactions to valacyclovir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>immuno-oncology</keyword>
  <keyword>tumor vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

